Work

Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 10 mg in Korean Adults With Type 2 Diabetes: A Multicentre, Randomised, Double‐Blind, Placebo‐Controlled Phase III Trial

Year: 2026
Type: article
Abstract: AIMS: To evaluate the efficacy and safety of anagliptin added to metformin and empagliflozin 10 mg in adults with Type 2 diabetes (T2D) with inadequate glycaemic control. MATERIALS AND METHODS: In this multicentre, randomised, double-blind, placebo-controlled Phase III trial, participants receiving metformin (≥ 1000 mg/day) plus empagliflozin 10 mg/day were randomised 1:1 to anagliptin 100 mg twice daily or placebo for 24 weeks. The primary endpoint was change in glycated haemoglobin (HbA1c) at Week 24 in the full analysis set, analysed using a mixed-effects model for repeated measures. Secondary endpoints included fasting plasma glucose (FPG), HbA1c target attainment, HOMA-β and safety. Glycaemic responder analyses were conducted post hoc. RESULTS: The full analysis set included 195 participants (anagliptin, n = 97; placebo, n = 98). At Week 24, LS mean HbA1c changes were -0.81% and -0.24%, respectively, yielding a treatment difference of -0.57% (95% CI -0.74 to -0.40; p < 0.0001). FPG was also significantly reduced (between-group difference -12.15 mg/dL, 95% CI -19.18 to -5.12; p = 0.0008). HbA1c ≤ 7.0% was achieved by 55.7% versus 25.5% of participants. HbA1c reductions ≥ 0.5% occurred in 68.0% versus 27.6%, and reductions ≥ 1.0% in 33.0% versus 9.2%. HOMA-β improved significantly with anagliptin (between-group difference 14.35, 95% CI 7.37-21.32; p < 0.0001). Treatment-emergent adverse events occurred in 22.7% and 17.2%, respectively; no hypoglycaemic events or deaths were reported. CONCLUSIONS: Anagliptin added to metformin and empagliflozin 10 mg provided confirmatory evidence of additional glycaemic efficacy in a separately randomised Korean population, increased glycaemic responder rates and improved estimated β-cell function, with acceptable short-term tolerability. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05814406.
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W7234247945
FWCI:
Cites: 17
Cited by:
Related to: 10